C20H29N5O3
Neat
387.48
Room Temperature
2227199-31-5; butyl 3-[(3R, 4R)-4-methyl-3-[methyl({7H-pyrrolo[2, 3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanoate; EXA92262Y4; Tofacitinib n-butyl 3-oxopropanoate; butyl3-[(3R, 4R)-4-methyl-3-[methyl({7H-pyrrolo[2, 3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanoate; BUTYL 3-[(3R, 4R)-4-METHYL-3-[METHYL({7H-PYRROLO[2, 3-D]PYRIMIDIN-4-YL)AMINO]PIPERIDIN-1-YL]-3-OXOPROPANOATE; butyl 3-[(3R, 4R)-4-methyl-3-[methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanoate; Butyl 3-((3R, 4R)-4-methyl-3-(methyl(7H-pyrrolo(2, 3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoate; Butyl 3-((3R, 4R)-4-Methyl-3-(methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoate; UNII-EXA92262Y4; CS-0166089; P18068; 1-PIPERIDINEPROPANOIC ACID, 4-METHYL-3-(METHYL-7H-PYRROLO(2, 3-D)PYRIMIDIN-4-YLAMINO)-.BETA.-OXO-, BUTYL ESTER, (3R, 4R)-; 1-Piperidinepropanoic acid, 4-methyl-3-(methyl-7H-pyrrolo(2, 3-d)pyrimidin-4-ylamino)-beta-oxo-, butyl ester, (3R, 4R)-; Butyl 3-((3R, 4R)-4-Methyl-3-(methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoate;; butyl 3-((3R, 4R)-4-methyl-3-(methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoate? (Tofacitinib Impurity; BUTYL3-[(3R, 4R)-4-METHYL-3-[METHYL({7H-PYRROLO[2 and 3-D]PYRIMIDIN-4-YL)AMINO]PIPERIDIN-1-YL]-3-OXOPROPANOATE
butyl 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanoate
InChI=1S/C20H29N5O3/c1-4-5-10-28-18(27)11-17(26)25-9-7-14(2)16(12-25)24(3)20-15-6-8-21-19(15)22-13-23-20/h6,8,13-14,16H,4-5,7,9-12H2,1-3H3,(H,21,22,23)/t14-,16+/m1/s1